Author: Boyington, Jeffrey C.; Joyce, M. Gordon; Sastry, Mallika; Stewart-Jones, Guillaume B. E.; Chen, Man; Kong, Wing-Pui; Ngwuta, Joan O.; Thomas, Paul V.; Tsybovsky, Yaroslav; Yang, Yongping; Zhang, Baoshan; Chen, Lei; Druz, Aliaksandr; Georgiev, Ivelin S.; Ko, Kiyoon; Zhou, Tongqing; Mascola, John R.; Graham, Barney S.; Kwong, Peter D.
Title: Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus Document date: 2016_7_27
ID: 1nbocmux_27
Snippet: As previously described [16] , the protective neutralization threshold was calculated by noting that the clinical administration of palivizumab (Synagis) at 15 mg/kg, leads to patient sera levels at trough of~40 μg/ml. This serum concentration provides protection in infants from severe disease and protection in cotton rats from RSV infection. In the neutralization assay described above, 40 μg/ml of palivizumab yields an EC 50 of 100......
Document: As previously described [16] , the protective neutralization threshold was calculated by noting that the clinical administration of palivizumab (Synagis) at 15 mg/kg, leads to patient sera levels at trough of~40 μg/ml. This serum concentration provides protection in infants from severe disease and protection in cotton rats from RSV infection. In the neutralization assay described above, 40 μg/ml of palivizumab yields an EC 50 of 100.
Search related documents:
Co phrase search for related documents- clinical administration and serum concentration: 1, 2, 3, 4
- clinical administration and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- describe neutralization assay and neutralization assay: 1, 2, 3, 4
- describe neutralization assay and severe disease: 1
- neutralization assay and protection provide: 1, 2, 3, 4, 5, 6
- neutralization assay and serum concentration: 1
- neutralization assay and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- neutralization threshold and protective neutralization threshold: 1
- neutralization threshold and severe disease: 1
- patient sera level and sera level: 1
- patient sera level and serum concentration: 1
- previously describe and severe disease: 1, 2
- protection provide and rsv infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- protection provide and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
- protection severe disease and rsv infection: 1, 2, 3
- protection severe disease and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
- rsv infection and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- sera level and serum concentration: 1
- sera level and severe disease: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date